India’s Cut-Price Generics Program Rebounds But Real Impact Still Limited

 
• By Anju Ghangurde
  
Indian Medicine
INDIA'S AMBITIOUS CUT-PRICE MEDICINES INITIATIVE STILL HAS A LONG WAY TO GO
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Policy & Regulation

More from Generics Bulletin